Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2
Study is designed to evaluate the safety and tolerability of increasing dose levels of the
Study is designed to evaluate the safety and tolerability of increasing dose levels of the
Newcastle City Council is looking for an investor to accelerate the growth of the region's
The North East Innovation Lab, part of Newcastle Hospitals has achieved a major milestone with
Atelerix Limited, which develops and markets innovative solutions for the storage and transport of cells,
Technology disrupter CellRev have appointed Ralph Pickles, former executive at ICI, CEO of Quorn Foods,
Alcyomics Limited® announces it is seeking partners toparticipate in validation tests of its unique in
Based at The Biosphere in Newcastle Helix, the facility is part of Newcastle Hospitals and